论文部分内容阅读
急性早幼粒细胞白血病(APL)的治疗取得了新的进展。在提高疗效的基础上进一步降低治疗的不良反应是近年来主要的研究方向之一,包括诱导方案的改进和巩固治疗策略的优化。以全反式维甲酸联合化疗为基础的治疗方案用于APL患者的治疗取得了良好的预后,提高了APL的完全缓解率。根据危险度不同进行分层治疗可以提高巩固治疗的疗效,而将微小残留病监测技术与抢先治疗相结合大大减少了血液学复发风险,使APL的治疗成为个体化治疗的典范。
New progress has been made in the treatment of acute promyelocytic leukemia (APL). On the basis of improving the curative effect, it is one of the main research directions to further reduce the adverse effects of the treatment in recent years, including the improvement of the induction program and the consolidation of the treatment strategy. The treatment regimen based on all-trans retinoic acid combined with chemotherapy has achieved a good prognosis for patients with APL and improved the complete remission rate of APL. Stratification treatment based on different degrees of risk can improve the efficacy of consolidation therapy. Combining minimal residual disease monitoring with preemptive treatment greatly reduces the risk of hematological relapse and makes APL treatment a model for individualized treatment.